Amphiphysin I is a 128 kD protein highly concentrated in nerve tenminals, where it has a putative role in endocytosis. It is a dominant autoantigen in patients with stiff-man syndrome associated with breast cancer, as well as in other paraneoplastic autoimmune neurological disorders. To elucidate the connection between amphiphysin I autoimmunity and cancer, we investigated its expression in breast cancer tissue. We report that amphiphysin I was expressed as two isoforms of 128 and 108 kD in the breast cancer of a patient with anti-amphiphysin I antibodies and paraneoplastic sensory neuronopathy. Amphiphysin I was also detectable at vari-
Introduction
Amphiphysin I is an SH3 domain-containing protein expressed at high levels in the nervous system (1, 2) . It is concentrated in axon terminals where it has a putative role in synaptic vesicle endocytosis (2) (3) (4) and growth cone dynamics (5) . Outside the nervous system, it was reported to have a restricted distribution (1, 6) . able levels in several other human breast cancer tissues and cell lines and at low levels in normal mammary tissue and a variety of other non-neuronal tissues. The predominant amphiphysin I isoform expressed outside the brain in humans is the 108 kD isoform which represents an altematively spliced variant of neuronal amphiphysin I missing a 42 amino acid insert. Our study suggests a link between amphiphysin I expression in cancer and amphiphysin I autoimmunity. The enhanced expression of amphiphysin I in some forms of cancer supports the hypothesis that amphiphysin family members may play a role in the biology of cancer cells.
Amphiphysin I has been identified as an autoantigen in human neurological paraneoplastic autoimmune diseases, often in association with breast cancer (6) (7) (8) (9) . The proposed scenario for these paraneoplastic syndromes is that (i) neoplastic transformation of a non-neuronal tissue results in ectopic expression of a neuronal protein in that tissue, and (ii) ectopic expression leads to anti-nervous system autoimmunity and neurological disease (10, 11) . Autoantigen expression in cancer has been reported in many cases (10, 11) , and it is possible that autoantigen expression may be involved in the biology of cancer.
Studies on members of the amphiphysin family have suggested a relationship between this protein family and the regulation of cell proliferation. Two proteins sharing blocks of homology with amphiphysin, Rvs161 and Rvs 167, are present in Saccaromyces cerevisiae (12) (13) (14) (15) . The RVS (reduced viability upon starvation) phenotype, which led to the identification of genes encoding these proteins, suggests the loss of regulatory feedback between availability of nutrients in the medium and growth (12, 13) . A homologue of amphiphysin I, amphiphysin II, has recently been described in mammalian cells. Amphiphysin II undergoes extensive alternative splicing, resulting in multiple isoforms with different tissue and subcellular distributions (16) (17) (18) (19) (20) (21) (22) . One of these isoforms, BIN1, was reported to interact with the MYC proto-oncogene and to act as a negative regulator of cell proliferation (17) . Another isoform was found to interact with the proto-oncogene cABL (23) . It is therefore of interest to characterize amphiphysin I expression in cancer cells.
We show here that amphiphysin I is more widely expressed in non-neuronal tissues than previously reported, although its concentration in non-neuronal tissues is much lower than in brain. We also demonstrate enhanced expression of amphiphysin I isoforms in several breast cancer tissues and cell lines, including the tissue of a patient with paraneoplastic sensory neuronopathy.
Materials and Methods

Antibodies
Rabbit polyclonal antibodies directed against amphiphysin I (CD5) (14) , amphiphysin I and II (CD9) (19) , synaptojanin (24) , dynamin (25) , synapsin I (26), and synaptophysin (27) were previously described. Anti-vimentin monoclonal antibodies were obtained from BoehringerMannheim. Human anti-amphiphysin I positive sera from paraneoplastic patients were previously described (6, 7) . Mouse monoclonal antibodies were generated as described (28, 29) using full-length His-tagged human amphiphysin I as the immunogen. Initial screening of hybrid clones was performed by Western blotting. The strongest 28 clones were selected and analyzed for their reactivity with amphiphysin I fragments expressed as GST fusion proteins in the pGEX-2T vector (Pharmacia) as previously described (14) (see also Fig. 4 ). The reactivity of the individual clones was as follows: Fragment 1: clones AIl,  AI2, AI6, AI7, AI8, AI9, AI17, AI18, A119, A120,   AI21, A122, AI23; Fragment 2: clones AI15,  AI16, AI24, AI25, AI26; Fragments 2 and 3:  clones AIll, AI12, AI13, AI27, (15) was constructed by polymerase chain reaction (PCR) from the human amphiphysin I complete cDNA using primers (forward) 5' -CTGCCGGGGAAGGAGTAAGTTT- 3' and (reverse) 5'-CCTAATCTAAGCGTCGGGTGA AGT-3'. This probe was radioactively labeled by primer direct labeling (32) (Fig. 1A) . The autoantibodies of the patient were directed primarily against the COOH terminal region of the amphiphysin I (Fig. 1B) , which is in agreement with results obtained previously with other paraneoplastic patients (ref. 14 and data not shown). We note that, whereas all sera of paraneoplastic patients have in common their reactivity with the COOHterminal region of amphiphysin I, (ref. 14 (Fig. 3A,B) . This band was recognized by polyclonal antibodies directed against amphiphysin I (Fig. 3) as well as by monoclonal antibodies directed against the five distinct regions of the protein (Fig. 4, lanes c) . Lower levels of the 108 kD band were detected in the cell line Hs578Bst, which was derived from histologically normal tissue outside the margin of the cancer from which the cell line Hs578T was derived (30) (Fig. 3A) . Other cell lines expressed amphiphysin I only at the limit of detectability. Neither the cancer tissue of Patient 692 nor the Hs578T cell line expressed elevated levels of synaptojanin I, dynamin I, and synapsin I, which suggests that the presence of amphiphysin I in the cell line and tissues was not due to neuroendocrine differentiation ( Fig. 3C and data not shown) . The expression of amphiphysin I in breast cell lines rules out the possibility that amphiphysin I expression in mammary tissue can be attributed to the presence of peripheral nerves.
We also searched for amphiphysin I immunoreactivity in normal and neoplastic human mammary tissues. We detected amphiphysin I in all tissues examined, which included 14 histologically normal breast tissues, 40 antibodies directed against either the COOH terminal region (Fig. 7) or the NH2-terminal region (not shown) of amphiphysin I revealed its expression in all tissues tested. The highest level of expression outside the brain was found in testis as previously reported (6), with only very low levels of expression in other tissues. In several human non-neuronal tissues, the 108 kD band was the predominant band, while amphiphysin I had a similar mobility in neuronal and non-neuronal tissues of the rat. (Fig. 9) . Similar results were obtained when overlapping regions of the entire coding sequence of amphiphysin I were amplified from total RNA of the Hs578T cell line by a series of RT-PCR reactions (not shown). The 126 base pair deletion predicts a corresponding deletion of 42 amino acids, which is less than expected for the electrophoretic difference between the 128 and 108 kD bands. However, amphiphysin I (128 kD isoform) is known to have an aberrantly low electrophoretic mobility (1) Fig. 6, lanes g and c, respectively. (B) The same blot as in B was probed with 1251-labeled protein A and a monoclonal antibody directed against the intermediate filament protein vimentin (arrowhead) to control for total protein loading. One and two asterisks correspond to the 128 and 108 kD amphiphysin I immunoreactive bands, respectively.
found to be responsible for this low mobility (14, 19) . In addition, in vitro translation and Western blot analysis of clone 3.4 with this 126 base pair deletion showed an electophoretic mobility identical to that of the 108 kD isoform from the Hs578T cell line (Fig 10) . Two of the breast cancers shown to overexpress amphiphysin I (Fig. 6) were also tested by RT-PCR and found to contain an identical 126 base pair deletion.
We next investigated whether an amphiphysin I mRNA with a similar deletion is present in normal human tissues, thus accounting for the 108 kD isoform present in these tissues. RT-PCR reactions performed on normal human heart, kidney, and mammary tissues revealed bands with a molecular weight identical to that seen in the Hs578T cell line. These bands were sequenced and found to contain the same 126 base pair deletion. Most likely, this deletion is the result of an alternative splicing event. We note that a homologous region undergoes alternative splicing in amphiphysin 11 (18) (19) (20) (21) .
Discussion
Amphiphysin I was implicated as the key autoantigen in stiff-man syndrome associated with breast cancer (6, 7) and subsequently as an autoantigen in other paraneoplastic disorders of the central nervous system (8, 9 (8) . Both amphiphysin I and amphiphysin I mRNA had been detected in some small-cell lung carcinomas (8) . The relationship between amphiphysin I expression and neoplastic growth in these latter tissues is unclear, as small-cell lung tumors have neuroendocrine properties and express significant levels of several neuronal proteins (36, 37) .
The enhanced expression of amphiphysin I isoforms in some cancers may be an epiphenomenon of neoplastic transformation. On the other hand, the possibility that amphiphysin I may be more closely linked to neoplastic transformation should be considered. As previously proposed (14) , a relationship of the amphiphysin protein family to the control of cell proliferation is suggested by yeast studies. Mutations of the two yeast genes that encode proteins with homology to amphiphysin I, the RVS161 and RVS167 genes, produce a phenotype characterized by reduced viability upon starvation (12, 13) in addition to defects in endocytosis, cell polarity, and actin function (15, 38) . Reduced viability upon starvation can be explained by the inability of yeast cells to stop growing when exposed to unfavorable growth conditions and it suggests impairment of growth regulatory mechanisms. A similar phenotype is produced by mutations in the yeast homologue of the ras oncogene (12, 13) .
Abnormal amphiphysin I expression may affect cell proliferation in mammalian cells through several mechanisms. Proteins of the amphiphysin family are thought to have pleotropic functions including roles in endocytosis (2, 3, 21, 38) , actin function (5, 13, 15, 23, 39) and cell growth control (17, 23) . As a protein implicated in clathrin-mediated endocytosis, amphiphysin I may modulate signaling of growth factor receptors by regulating their internalization (3, 21, 40) . Alternatively, it may affect signal transduction from the cell surface by actions on the actin cytoskeleton (5,38) or on protein-protein interaction cascades mediated through its SH3 domain (23, 41) . Finally, a more direct potential role of amphiphysin family members in the regulation of cell proliferation is suggested by the identification of amphiphysin II isoforms as either MYC -interacting proteins with some properties of a tumor suppressor (17) or as cABLinteracting proteins (23) . The finding that amphiphysin I is overexpressed, rather than underexpressed, in some cancers, is in contrast to a putative role of amphiphysin family members as negative regulators of cell growth. However, amphiphysin I overexpression, or the overexpression of a specific isoform, may have a dominant negative role. Amphiphysin I forms heterodimers with amphiphysin II (ref. 21 and our unpublished observations) and it was reported that over expression of amphiphysin I, but not concomitant overexpression of both amphiphysin I and II, has a dominant negative affect on clathrin-mediated endocytosis (21) .
Irrespective of whether amphiphysin I expression in cancer cells is an event that lies upstream or downstream of neoplastic transformation, enhanced amphiphysin I-expression in some cancers and its implication in autoimmune paraneoplastic disease predict that further studies of this protein may aid in understanding important human diseases.
